Redburn, the independent equity research and execution firm, celebrates its 15th anniversary. Founded in 2003 as a greenfield start up, Redburn has grown to be one of the leading UK and European research and execution firms. Redburn has 195 employees and offices in London, New York, Paris and Madrid. The company’s capabilities span equity research, sales, access and execution.
The UK and European equity research activity covers 20 sectors and has a team of 65 top rated analysts, marketed through a global sales force. The research team at Redburn are known for high quality research that leads with industrial expertise to generate commercial insight and alpha, as well as leading quantitative, technical, and expert access offerings.
The execution team, 34 strong, trade European and US equities on behalf of institutional and hedge fund clients. They focus on delivering differentiated technology and service in high touch, algorithmic and portfolio trading. To ensure excellence in its execution offering, Redburn design technology which provides access to a broad spectrum of liquidity in a range of markets.
In recent months, Redburn has strengthened its execution offering with the appointment of James Kebel in London, Ryan Maguire in New York and Mike Seigne as a new Global Head of Execution Services. In Research Services Redburn has recruited Simon Baker as Head of Pharmaceutical research and Jonathan De Pracontal to reinforce Redburn’s capabilities in mainland Europe.
Jeremy Evans, co-founder and Senior Partner of Redburn, commented: “With fifteen years as an outsider, disrupting the incumbents, and with the flexibility and entrepreneurialism that accompanies being a smaller firm, Reburn has been and will be in the vanguard of the transformation in the terms of trade caused by MIFID II.